Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Belite Bio, Inc. ADR ( (BLTE) ) has shared an update.
On February 5, 2025, Belite Bio, Inc announced a registered direct offering involving the sale of 258,309 American Depositary Shares and accompanying warrants to a new healthcare investor, aiming to raise approximately $15 million. The company plans to utilize the net proceeds for working capital and general corporate purposes, potentially augmenting its financial position in the biopharmaceutical industry focused on retinal diseases.
More about Belite Bio, Inc. ADR
Belite Bio, Inc is a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics for degenerative retinal diseases with significant unmet medical needs, such as Stargardt disease and Geographic Atrophy in advanced dry age-related macular degeneration, as well as certain metabolic diseases.
YTD Price Performance: -10.33%
Average Trading Volume: 58,246
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.79B
For detailed information about BLTE stock, go to TipRanks’ Stock Analysis page.